<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35346783</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>11</Day></DateCompleted><DateRevised><Year>2023</Year><Month>06</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-5921</ISSN><JournalIssue CitedMedium="Internet"><Volume>147</Volume><PubDate><Year>2022</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Journal of clinical epidemiology</Title><ISOAbbreviation>J Clin Epidemiol</ISOAbbreviation></Journal><ArticleTitle>Joint modeling of endpoints can be used to answer various research questions in randomized clinical trials.</ArticleTitle><Pagination><StartPage>32</StartPage><EndPage>39</EndPage><MedlinePgn>32-39</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jclinepi.2022.03.009</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0895-4356(22)00070-1</ELocationID><Abstract><AbstractText Label="OBJECTIVES">Correlated longitudinal and time-to-event outcomes, such as the rate of cognitive decline and the onset of Alzheimer's disease, are frequent (co-)primary and key secondary endpoints in randomized clinical trials (RCTs). Despite their biological associations, these types of data are often analyzed separately, leading to loss of information and increases in bias. In this paper, we set out how joint modeling of longitudinal and time-to-event endpoints can be used in RCTs to answer various research questions.</AbstractText><AbstractText Label="STUDY DESIGN AND SETTING">The key concepts of joint models are introduced and illustrated for a completed trial in amyotrophic lateral sclerosis.</AbstractText><AbstractText Label="RESULTS">The output of a joint model can be used to answer different clinically relevant research questions, where the interpretation of effect estimates and those obtained from conventional methods are similar. Albeit joint models have the potential to overcome the limitations of commonly used alternatives, they require additional assumptions regarding the distributions, as well as the associations between two endpoints.</AbstractText><AbstractText Label="CONCLUSION">Improving the uptake of joint models in RCTs may start by outlining the exact research question one seeks to answer, thereby determining how best to prespecify the model and defining the parameter that should be of primary interest.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Eijk</LastName><ForeName>Ruben P A</ForeName><Initials>RPA</Initials><AffiliationInfo><Affiliation>Department of Biomedical Data Science and Center for Innovative Study Design, School of Medicine, Stanford University, Stanford, CA, USA; Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands. Electronic address: r.p.a.vaneijk-2@umcutrecht.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roes</LastName><ForeName>Kit C B</ForeName><Initials>KCB</Initials><AffiliationInfo><Affiliation>Department of Health Evidence, Section Biostatistics, Radboud Medical Center Nijmegen, Nijmegen, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Leonard H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, University Medical Center Utrecht, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biomedical Data Science and Center for Innovative Study Design, School of Medicine, Stanford University, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA124435</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL089778</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR003142</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>03</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Epidemiol</MedlineTA><NlmUniqueID>8801383</NlmUniqueID><ISSNLinking>0895-4356</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015982" MajorTopicYN="N">Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">Clinical trials</Keyword><Keyword MajorTopicYN="N">Informative censoring</Keyword><Keyword MajorTopicYN="N">Joint modeling</Keyword><Keyword MajorTopicYN="N">Longitudinal</Keyword><Keyword MajorTopicYN="N">Time-to-event</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>12</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>3</Month><Day>29</Day><Hour>5</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35346783</ArticleId><ArticleId IdType="mid">NIHMS1793876</ArticleId><ArticleId IdType="pmc">PMC10266556</ArticleId><ArticleId IdType="doi">10.1016/j.jclinepi.2022.03.009</ArticleId><ArticleId IdType="pii">S0895-4356(22)00070-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>van Oudenhoven FM, Swinkels SHN, Hartmann T, Soininen H, van Hees AMJ, Rizopoulos D. Using joint models to disentangle intervention effect types and baseline confounding: an application within an intervention study in prodromal Alzheimer&#x2019;s disease with Fortasyn Connect. BMC Med Res Methodol. 2019;19:163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6659198</ArticleId><ArticleId IdType="pubmed">31345172</ArticleId></ArticleIdList></Reference><Reference><Citation>Ediebah DE, Galindo-Garre F, Uitdehaag BM, Ringash J, Reijneveld JC, Dirven L, et al. Joint modeling of longitudinal health-related quality of life data and survival. Qual Life Res. 2015;24:795&#x2013;804.</Citation><ArticleIdList><ArticleId IdType="pubmed">25311306</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen LM, Ibrahim JG, Chu H. Sample size and power determination in joint modeling of longitudinal and survival data. Stat Med. 2011;30:2295&#x2013;309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3278672</ArticleId><ArticleId IdType="pubmed">21590793</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibrahim JG, Chu H, Chen LM. Basic concepts and methods for joint models of longitudinal and survival data. J Clin Oncol. 2010;28:2796&#x2013;801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4503792</ArticleId><ArticleId IdType="pubmed">20439643</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawrence Gould A, Boye ME, Crowther MJ, Ibrahim JG, Quartey G, Micallef S, et al. Joint modeling of survival and longitudinal non-survival data: current methods and issues. Report of the DIA Bayesian joint modeling working group. Stat Med. 2015;34:2181&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4677775</ArticleId><ArticleId IdType="pubmed">24634327</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizopoulos D Joint models for longitudinal and time-to-event data : with applications in R. Boca Raton: CRC Press; 2012.</Citation></Reference><Reference><Citation>Levine SZ, Goldberg Y, Samara M, Davis JM, Leucht S. Joint modeling of dropout and outcome in three pivotal clinical trials of schizophrenia. Schizophr Res. 2015;164:122&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">25790904</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Hernandez A, Perez T, Pardo MDC, Rizopoulos D. MMRM vs joint modeling of longitudinal responses and time to study drug discontinuation in clinical trials using a &#x201c;de jure&#x201d; estimand. Pharm Stat. 2020;19:909&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">32725810</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Eijkemans MJC, Rizopoulos D, van den Berg LH, Nikolakopoulos S. Comparing methods to combine functional loss and mortality in clinical trials for amyotrophic lateral sclerosis. Clin Epidemiol. 2018;10:333&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5865572</ArticleId><ArticleId IdType="pubmed">29593436</ArticleId></ArticleIdList></Reference><Reference><Citation>Deslandes E, Chevret S. Assessing surrogacy from the joint modelling of multivariate longitudinal data and survival: application to clinical trial data on chronic lymphocytic leukaemia. Stat Med. 2007;26:5411&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">18058850</ArticleId></ArticleIdList></Reference><Reference><Citation>Spertus JV, Hatfield LA, Cohen DJ, Arnold SV, Ho M, Jones PG, et al. Integrating Quality of Life and Survival Outcomes in Cardiovascular Clinical Trials. Circ Cardiovasc Qual Outcomes. 2019;12:e005420.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6579042</ArticleId><ArticleId IdType="pubmed">31189406</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudell M, Kolamunnage-Dona R, Tudur-Smith C. Joint models for longitudinal and time-to-event data: a review of reporting quality with a view to meta-analysis. BMC Med Res Methodol. 2016;16:168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5139124</ArticleId><ArticleId IdType="pubmed">27919221</ArticleId></ArticleIdList></Reference><Reference><Citation>Asgari S, Khalili D, Zayeri F, Azizi F, Hadaegh F. Dynamic prediction models improved the risk classification of type 2 diabetes compared with classical static models. J Clin Epidemiol. 2021;140:33&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pubmed">34455032</ArticleId></ArticleIdList></Reference><Reference><Citation>Farcomeni A, Pareek B, Ghosh P. Discussion on &#x2018;Joint modeling of survival and longitudinal non-survival data&#x2019; by Gould et al. Stat Med. 2015;34:2198&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">26032837</ArticleId></ArticleIdList></Reference><Reference><Citation>Gould AL, Boye ME, Crowther MJ, Ibrahim JG, Quartey G, Micallef S, et al. Responses to discussants of &#x2018;Joint modeling of survival and longitudinal non-survival data: current methods and issues. report of the DIA Bayesian joint modeling working group&#x2019;. Stat Med. 2015;34:2202&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4682363</ArticleId><ArticleId IdType="pubmed">26032839</ArticleId></ArticleIdList></Reference><Reference><Citation>Piepers S, Veldink JH, de Jong SW, van der Tweel I, van der Pol WL, Uijtendaal EV, et al. Randomized sequential trial of valproic acid in amyotrophic lateral sclerosis. Ann Neurol. 2009;66:227&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">19743466</ArticleId></ArticleIdList></Reference><Reference><Citation>Westeneng HJ, Debray TPA, Visser AE, van Eijk RPA, Rooney JPK, Calvo A, et al. Prognosis for patients with amyotrophic lateral sclerosis: development and validation of a personalised prediction model. Lancet Neurol. 2018;17:423&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">29598923</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Nikolakopoulos S, Roes KCB, Kendall L, Han SS, Lavrov A, et al. Challenging the Established Order: Innovating Clinical Trials for Amyotrophic Lateral Sclerosis. Neurology. 2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8456357</ArticleId><ArticleId IdType="pubmed">34315786</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169:13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicines Agency.
Guideline on clinical investigation of medicinal products for the treatment of amyotrophic lateral sclerosis. https://www.ema.europa.eu/documents/scientific-guideline/guideline-clinical-investigation-medicinal-products-treatment-amyotrophic-lateral-sclerosis_en.pdf; 2016. p. Accessed 19 Nov 2021.</Citation></Reference><Reference><Citation>Food Drug Administration Center for Drugs Evaluation Research.
Guidance for Industry: Amyotrophic Lateral Sclerosis: Developing Drugs for Treatment
https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM596718.pdf; 2021. p. Accessed 4 May 2020.</Citation></Reference><Reference><Citation>van Eijk RPA, Nikolakopoulos S, Ferguson TA, Liu D, Eijkemans MJC, van den Berg LH. Increasing the efficiency of clinical trials in neurodegenerative disorders using group sequential trial designs. J Clin Epidemiol. 2018;98:80&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">29486281</ArticleId></ArticleIdList></Reference><Reference><Citation>van Oudenhoven FM, Swinkels SHN, Ibrahim JG, Rizopoulos D. A marginal estimate for the overall treatment effect on a survival outcome within the joint modeling framework. Stat Med. 2020;39:4120&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7674249</ArticleId><ArticleId IdType="pubmed">32838484</ArticleId></ArticleIdList></Reference><Reference><Citation>ICH E9 (R1).
Addendum on estimands and sensitivity analysis in clinical trials to the guideline on statistical principles for clinical trials. https://database.ich.org/sites/default/files/E9-R1_Step4_Guideline_2019_1203.pdf; 2019. p. Accessed 20 Nov 2021.</Citation></Reference><Reference><Citation>Oude Rengerink K, Mitroiu M, Teerenstra S, Petavy F, Roes KCB. Rethinking the intention-to-treat principle: one size does not fit all. J Clin Epidemiol. 2020;125:198&#x2013;200.</Citation><ArticleIdList><ArticleId IdType="pubmed">32380178</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk RPA, Roes KCB, de Greef-van der Sandt I, van den Berg LH, Lu Y Functional loss and mortality in randomized clinical trials for amyotrophic lateral sclerosis: to combine, or not to combine - that is the estimand. Clin Pharmacol Ther. 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8940672</ArticleId><ArticleId IdType="pubmed">35076930</ArticleId></ArticleIdList></Reference><Reference><Citation>Wulfsohn MS, Tsiatis AA. A Joint Model for Survival and Longitudinal Data Measured with Error. Biometrics. 1997;53:330&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9147598</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsefri M, Sudell M, Garcia-Finana M, Kolamunnage-Dona R. Bayesian joint modelling of longitudinal and time to event data: a methodological review. BMC Med Res Methodol. 2020;20:94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7183597</ArticleId><ArticleId IdType="pubmed">32336264</ArticleId></ArticleIdList></Reference><Reference><Citation>Chesnaye NC, Tripepi G, Dekker FW, Zoccali C, Zwinderman AH, Jager KJ. An introduction to joint models-applications in nephrology. Clin Kidney J. 2020;13:143&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7147305</ArticleId><ArticleId IdType="pubmed">32296517</ArticleId></ArticleIdList></Reference><Reference><Citation>Colantuoni E, Scharfstein DO, Wang C, Hashem MD, Leroux A, Needham DM, et al. Statistical methods to compare functional outcomes in randomized controlled trials with high mortality. BMJ. 2018;360:j5748.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5751848</ArticleId><ArticleId IdType="pubmed">29298779</ArticleId></ArticleIdList></Reference><Reference><Citation>Olivier T, Haslam A, Prasad V. Informative censoring due to missing data in quality of life was inadequately assessed in most oncology randomized controlled trials. J Clin Epidemiol. 2021;139:80&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">34311054</ArticleId></ArticleIdList></Reference><Reference><Citation>Schoenfeld DA, Richter JR. Nomograms for calculating the number of patients needed for a clinical trial with survival as an endpoint. Biometrics. 1982;38:163&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">7082758</ArticleId></ArticleIdList></Reference><Reference><Citation>Berry JD, Miller R, Moore DH, Cudkowicz ME, van den Berg LH, Kerr DA, et al. The Combined Assessment of Function and Survival (CAFS): a new endpoint for ALS clinical trials. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:162&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">23323713</ArticleId></ArticleIdList></Reference><Reference><Citation>Price DL, Wang Y. Commentary on &#x2018;Joint modeling of survival and longitudinal non-survival data: current methods and issues&#x2019;. Stat Med. 2015;34:2200&#x2013;1.</Citation><ArticleIdList><ArticleId IdType="pubmed">26032838</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Psioda MA, Ibrahim JG. Bayesian design of clinical trials using joint models for longitudinal and time-to-event data. Biostatistics. 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9216589</ArticleId><ArticleId IdType="pubmed">33155038</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>